These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24501286)

  • 21. Engineered cell therapy for cancer gets thumbs up from FDA advisers.
    Ledford H
    Nature; 2017 Jul; 547(7663):270. PubMed ID: 28726836
    [No Abstract]   [Full Text] [Related]  

  • 22. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
    Gilham DE; Debets R; Pule M; Hawkins RE; Abken H
    Trends Mol Med; 2012 Jul; 18(7):377-84. PubMed ID: 22613370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer T cell therapy expands.
    Becknell B; Caligiuri MA
    Nat Med; 2003 Mar; 9(3):257-8. PubMed ID: 12612567
    [No Abstract]   [Full Text] [Related]  

  • 24. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.
    Cieri N; Mastaglio S; Oliveira G; Casucci M; Bondanza A; Bonini C
    Immunol Rev; 2014 Jan; 257(1):165-80. PubMed ID: 24329796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The T-body approach: redirecting T cells with antibody specificity.
    Eshhar Z
    Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Boosting the Potency of T-cell Therapies.
    Poh A
    Cancer Discov; 2016 Apr; 6(4):338. PubMed ID: 26960342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
    Stauss HJ; Morris EC
    Gene Ther; 2013 Nov; 20(11):1029-32. PubMed ID: 23804078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Supernatural T cells: genetic modification of T cells for cancer therapy.
    Kershaw MH; Teng MW; Smyth MJ; Darcy PK
    Nat Rev Immunol; 2005 Dec; 5(12):928-40. PubMed ID: 16322746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical development of T cell receptor gene therapy.
    Bendle GM; Haanen JB; Schumacher TN
    Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cellular immunotherapy with genetically engineered T-cell therapy for malignancies].
    Fujiwara H
    Rinsho Ketsueki; 2011 May; 52(5):243-55. PubMed ID: 21646769
    [No Abstract]   [Full Text] [Related]  

  • 31. Regulating CAR T Cells: A Remote Control Approach.
    Cancer Discov; 2016 Sep; 6(9):936-7. PubMed ID: 27412488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
    Berry LJ; Moeller M; Darcy PK
    Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
    Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic modification of T cells for cancer therapy.
    Imai C; Campana D
    J Biol Regul Homeost Agents; 2004; 18(1):62-71. PubMed ID: 15323362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
    Chmielewski M; Hombach AA; Abken H
    Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced T cell receptor gene therapy for cancer.
    Kieback E; Uckert W
    Expert Opin Biol Ther; 2010 May; 10(5):749-62. PubMed ID: 20201709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetically modulating T-cell function to target cancer.
    Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
    Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors.
    Alvarez-Vallina L; Yañez R; Blanco B; Gil M; Russell SJ
    Cancer Gene Ther; 2000 Apr; 7(4):526-9. PubMed ID: 10811469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploiting alloreactivity for tumour immunotherapy.
    Stauss HJ; Xue S; Gillmore R; Gao L; Bendle G; Holler A; Downs AM; Morris E
    Vox Sang; 2004 Jul; 87 Suppl 2():227-9. PubMed ID: 15209922
    [No Abstract]   [Full Text] [Related]  

  • 40. Strategies and rules for tuning TCR-derived therapy.
    Mo G; Lu X; Wu S; Zhu W
    Expert Rev Mol Med; 2023 Dec; 26():e4. PubMed ID: 38095091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.